Table 2.
Short-term mortality by CKD status (n = 4743 for pneumonia, n = 1058 for sepsis)a
| Number (column %) | 28-Day mortality (row %) | 90-Day mortality (row %) | RRs for 28-day mortality (95% CI) |
RRs for 90-day mortality (95% CI) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted for demographicsb | adjusted for non-CVD co-morbiditiesc | Fully adjustedd | Adjusted for demographicsb | Adjusted for non-CVD co-morbiditiesc | Fully adjustedd | |||||
| Pneumonia | ||||||||||
| Proteinuria (adjusted for eGFR) | ||||||||||
| Yes | 1611 (34.0) | 499 (31.0) | 625 (38.8) | 1.07 (0.97–1.17) | 1.07 (0.98–1.18) | 1.07 (0.98–1.18) | 1.05 (0.97–1.13) | 1.06 (0.98–1.14) | 1.05 (0.98–1.14) | |
| No | 3132 (66.0) | 907 (29.0) | 1150 (36.7) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |
| eGFR (mL/min/1.73 m2) (adjusted for proteinuria) | ||||||||||
| <30 | <15 | 23 (0.5) | 12 (52.2) | 12 (52.2) | 1.27 (1.10–1.47) | 1.31 (1.13–1.52) | 1.30 (1.12–1.52) | 1.26 (1.12–1.42) | 1.29 (1.14–1.45) | 1.27 (1.12–1.43) |
| 15–29 | 263 (5.6) | 110 (41.8) | 139 (52.9) | |||||||
| 30–44 | 764 (16.1) | 265 (34.7) | 336 (44.0) | 0.98 (0.86–1.10) | 0.99 (0.88–1.13) | 0.99 (0.88–1.12) | 1.02 (0.93–1.13) | 1.04 (0.94–1.15) | 1.03 (0.94–1.14) | |
| 45–60 | 1162 (24.5) | 332 (28.6) | 418 (36.0) | 0.91 (0.82–1.02) | 0.94 (0.84–1.04) | 0.93 (0.84–1.04) | 0.91 (0.83–1.00) | 0.93 (0.85–1.02) | 0.92 (0.84–1.01) | |
| ≥60 | 2531 (53.4) | 687 (27.1) | 870 (34.4) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |
| Total | 4743 | 1406 (29.6) | 1775 (37.4) | |||||||
| Sepsis | ||||||||||
| Proteinuria (adjusted for eGFR) | ||||||||||
| Yes | 358 (33.8) | 128 (35.8) | 159 (44.4) | 0.98 (0.82–1.17) | 1.01 (0.85–1.21) | 1.01 (0.85–1.21) | 0.98 (0.86–1.13) | 0.96 (0.84–1.10) | 0.96 (0.84–1.10) | |
| No | 700 (66.2) | 249 (35.6) | 309 (44.1) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |
| eGFR (mL/min/1.73 m2) (adjusted for proteinuria) | ||||||||||
| <30 | <15 | 8 (0.8) | 2 (25.0) | 5 (62.5) | 1.42 (1.10–1.84) | 1.41 (1.08–1.84) | 1.37 (1.05–1.79) | 1.39 (1.14–1.70) | 1.32 (1.07–1.63) | 1.32 (1.07–1.64) |
| 15–29 | 62 (5.9) | 32 (51.6) | 39 (62.9) | |||||||
| 30–44 | 190 (18.0) | 88 (46.3) | 103 (54.2) | 1.25 (1.01–1.55) | 1.24 (0.99–1.55) | 1.24 (0.99–1.54) | 1.14 (0.96–1.36) | 1.12 (0.94–1.33) | 1.11 (0.94–1.32) | |
| 45–60 | 232 (21.9) | 76 (32.8) | 95 (41.0) | 0.95 (0.75–1.19) | 0.91 (0.72–1.15) | 0.91 (0.72–1.14) | 0.92 (0.77–1.11) | 0.89 (0.74–1.07) | 0.89 (0.75–1.07) | |
| ≥60 | 566 (53.5) | 179 (31.6) | 226 (39.9) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |
| Total | 1058 | 377 (35.6) | 468 (44.2) | |||||||
aExcluding patients with missing smoking or HbA1C data.
bAge, gender, socio-economic status, onset prior to 1 April 2004.
cAge, gender, socio-economic status, onset prior to 1 April 2004, smoking status, chronic lung disease, dementia, cancer, connective tissue disorders, hypertension, cerebrovascular disease, diabetes medications, latest HbA1C.
dAge, gender, socio-economic status, onset prior to 1 April 2004, smoking status, chronic lung disease, dementia, cancer, connective tissue disorders, hypertension, cerebrovascular disease, diabetes medications, latest HbA1C, congestive heart failure, ischaemic heart disease.